Alexandra Drakaki MD, PhDAssistant Professor of Medicine and Urology; Director - Genitourinary Medical Oncology Program, Division of Hematology/Oncology and Institute of Urologic Oncology, UCLA, Los Angeles, California
Alexandra Drakaki is an MD, PhD and board certified Oncologist / Hematologist. She received her training in Internal Medicine at a Tuft's University affiliate program while she completed her hematology / oncology training at Beth Israel Deaconess Medical Center at Harvard Medical School and her research fellowship at Dana Farber Cancer Center Harvard Medical School in Boston. She specializes in genitourinary cancers and specifically cancers of the bladder, testis, urethra, prostate and kidney.
She is the Primary Investigator in several ongoing clinical trials that are testing novel drugs in the field. Her research interest is studying the role of a novel class of genes, named non-coding RNAs, including microRNAs and linkRNAs in genitourinary malignancies.
Furthermore, she is part of the Translational Oncology Research Laboratory at UCLA in which researchers are working on drug development by using novel technologies for breakthrough discoveries.
Recent Contributions to PracticeUpdate:
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin ± Panitumumab for Advanced Urothelial Carcinoma
- A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients With Metastatic Kidney Cancer
- An Overview of PD-1 Inhibitors in Bladder Cancer
- Non–Muscle Invasive and Muscle-Invasive Bladder Cancer Data From ASCO GU 2017